Eli Lilly scored another win against diabetes as the company’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide won approval under Priority Review from the U.S. Food and Drug Administration.
Alabama lawmakers passed a bill on Thursday that would criminalize gender-affirming healthcare for transgender youth, with a threat of 10 years in prison for medical providers.
Agile Therapeutics Inc. announced the launch of the women’s healthcare company’s first consumer commercial intended to increase awareness of the Twirla weekly birth control patch.
With the Omicron surge waning – at least in the United States – there is speculation that the COVID-19 pandemic may be in its end stages, although some experts warn that this could be premature.
Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).
Astellas Pharma studied the potential of fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, against hot flashes in a series of double-blinded and placebo-controlled trials.
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.
The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).
Ireland’s Horizon Therapeutics became the first to win regulatory approval in the United States for the treatment of Thyroid Eye Disease (TED), a progressive autoimmune disorder that can threaten the vision of those afflicted.
Veru Inc. said a higher dose of the company’s experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study.
Reuters